icc guideline revisions for patients with mds: improving diagnosis in mds
Published 10 months ago • 110 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
3:16
revisions to the icc and who classifications of aml and mds
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
1:33
updates to the icc classification of aml
-
1:41
an overview of the mds diagnosis pathway
-
3:01
challenges in distinguishing between pre-mds states and mds, and approaches to improve diagnosis
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
1:40
mds 2023 highlights: classification and risk stratification systems & progression from ch to mds
-
3:18
midiagnostics' complete blood count (cbc) - blood analysis for diagnosis and monitoring
-
4:41
acute myeloid leukemia survival rate and outlook
-
3:46
introduction to homologous recombination deficiency (hrd) assessment
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
2:22
improve study: mrd assessment as an endpoint to define treatment length and intensity in cll
-
1:51
factors driving the transformation of chip to mds
-
2:03
preliminary results of a phase ii study of fedratinib in patients with mds/mpn and cnl
-
1:57
combining molecular and clinical data to predict survival & transformation risk in patients with mds
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
4:44
establishing the clinical benchmark of azacitidine in patients with mds
-
2:41
an overview of the latest advances in hematology
-
0:51
similarities between the who and icc classifications for mds & the need to create a unified approach
-
1:59
the role of inflammatory signaling pathways in lower-risk mds